Sign in →

Test Code CH8B Chromogenic Factor VIII Inhibitor Bethesda Titer, Plasma


Specimen Required


Only orderable as part of a profile. For more information see CHF8P / Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma.

Specimen Type: Platelet-poor plasma

Collection Container/Tube: Light-blue top (3.2% sodium citrate)

Submission Container/Tube: Plastic vials

Specimen Volume: 2 mL in 2 plastic vials, each containing 1 mL

Collection Instructions:

1. Specimen must be collected prior to factor replacement therapy.

2. If collecting sample through a port/line, be sure to waste the appropriate amount prior to collection.

3. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.

4. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.

5. Aliquot plasma (1 mL per aliquot) into 2 separate plastic vials leaving 0.25 mL in the bottom of centrifuged vial.

6. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally -40° C or below.

Additional Information:

1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.

2. Each coagulation assay requested should have its own vial.


Useful For

Detecting the presence and titer of a specific factor inhibitor directed against coagulation factor VIII

 

This test is not useful for detecting the presence of inhibitors directed against other clotting factors and will not detect the presence of lupus anticoagulants.

Method Name

Only orderable as part of a profile. For more information see CHF8P / Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma.

 

Chromogenic

Reporting Name

Chromogenic FVIII Inhibitor Titer,P

Specimen Type

Plasma Na Cit

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Plasma Na Cit Frozen 14 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
IV heparin contamination Reject

Clinical Information

Factor VIII (FVIII) inhibitors are IgG antibodies directed against coagulation FVIII that typically result in development of potentially life-threatening hemorrhage. These antibodies may be alloimmune: developing in patients with congenital FVIII deficiency (hemophilia A) in response to therapeutic infusions of factor VIII concentrate or autoimmune: occurring in patients without hemophilia (not previously factor VIII deficient) either spontaneously, during pregnancy, or in association with autoimmune diseases.

Reference Values

Only orderable as part of a profile. For more information see CHF8P / Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma.

 

≤0.5 Bethesda Units

Day(s) Performed

Monday through Friday

Report Available

2 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

85335